<DOC>
	<DOCNO>NCT00303758</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , fluorouracil , leucovorin , cisplatin , gemcitabine , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) give different way may kill tumor cell . It yet know combination chemotherapy regimen effective treat metastatic pancreatic cancer . PURPOSE : This randomized phase III trial study two different combination chemotherapy regimens compare well work treat patient metastatic pancreatic cancer remove surgery .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Metastatic Pancreatic Cancer That Can Be Removed By Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare overall survival patient unresectable metastatic pancreatic cancer treat fluorouracil , leucovorin calcium , cisplatin follow gemcitabine hydrochloride v gemcitabine hydrochloride follow fluorouracil , leucovorin calcium , cisplatin . Secondary - Compare progression-free survival patient treat regimen . - Compare toxicity regimens patient . - Compare quality life patient treat regimen . - Compare percentage patient need second-line therapy . - Compare duration hospitalization patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord ECOG performance status ( 0 1 v 2 ) , participate center , location tumor ( ampullar region v location ) , infusion rate gemcitabine hydrochloride ( 30 v 100 minute ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive leucovorin calcium IV 2 hour day 1 , cisplatin IV 1 hour day 1 2 , fluorouracil IV 46 hour day 1 2 . Treatment repeat every 2 week absence disease progression unacceptable toxicity . Patients disease progression also receive gemcitabine hydrochloride IV 30 100 minute weekly 7 week . Patients receive gemcitabine hydrochloride IV day 1 , 8 , 15 . Courses repeat every 4 week absence disease progression unacceptable toxicity . - Arm II : Patients receive gemcitabine hydrochloride IV 30 100 minute weekly 7 week absence disease progression unacceptable toxicity . Patients disease progression receive fluorouracil , leucovorin calcium , cisplatin arm I . Quality life assess baseline every 2 month . After completion study therapy , patient follow periodically 2 year . PROJECTED ACCRUAL : A total 202 patient accrue study .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm adenocarcinoma pancreas ampulla Metastatic disease Unresectable disease Measurable disease , meet follow criterion : No prior radiotherapy site measurable disease Diameter &gt; 10 mm spiral CT scan MRI OR &gt; 20 mm conventional method No brain metastases PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy &gt; 2 month No contraindication chemotherapy Creatinine clearance &gt; 60 mL/min Absolute neutrophil count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Alkaline phosphatase &lt; 5 time normal Bilirubin ≤ 3 mg/dL No coronary insufficiency No symptomatic cardiac disease Good hydration possible No ChildPugh class B C cirrhosis No malignancy except basal cell skin cancer carcinoma situ cervix Not pregnant nursing Negative pregnancy test PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior palliative adjuvant chemotherapy At least 4 week since prior radiotherapy No radiotherapy 4 week study therapy No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2006</verification_date>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>